Skip to search formSkip to main contentSkip to account menu

SK&F 105809

Known as: SKF-105809 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Imidazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1994
1994
Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responses.
1992
1992
Beneficial effects of SK&F 105809, a novel cytokine-suppressive agent, in murine models of endotoxin shock.
SK&F 105809 is a structurally novel dual inhibitor of lipoxygenase and cyclooxygenase-mediated arachidonic acid (AA) metabolism… 
1992
1992
THE MIXED LIPOXYGENASE/CYCLOOXYGENASE INHIBITOR SK&F 105809 REDUCES CEREBRAL EDEMA AFTER CLOSED HEAD INJURY IN RAT
Closed head injury in rats induces edema formation, which is indicated by a decrease in cerebral specific gravity and an increase… 
1991
1991
Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism.
The analgetic activity of inhibitors of 5-lipoxygenase (5-LO) and cyclooxygenase (CO) was investigated using rat Randall-Selitto… 
1991
1991
Pharmacology of the pyrroloimidazole, SK&F 105809--II. Antiinflammatory activity and inhibition of mediator production in vivo.
1991
1991
Pharmacology of the pyrroloimidazole, SK&F 105809--I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.
1990
1990
Pharmacological profile of SK&F 105809, a dual inhibitor of arachidonic acid metabolism.
The effects of SK&F 105809, 6,7,-dihydro-2-[4(methylsulfinyl) phenyl]-3-(4-pyridyl) -5[H]-pyrrolo[1,2-a] imidazole, on eicosanoid… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)